FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058202320> ?p ?o ?g. }

• W2058202320 endingPage "451" @default.
• W2058202320 startingPage "442" @default.
• W2058202320 abstract "Enoxaparin is a low-molecular-weight heparin indicated in Europe and North America for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopedic surgery. Registration trials of enoxaparin have been conducted primarily in Caucasian populations, and the efficacy and safety of enoxaparin in Japanese patients have not been demonstrated. We evaluated three dosage regimens of postoperative enoxaparin in Japanese patients undergoing elective total hip or knee arthroplasty. Two multicenter, randomized, double-blind studies enrolled 436 and 396 Japanese adults undergoing total hip or knee arthroplasty, respectively. The dosage regimens of enoxaparin were 20 mg once daily (qd), 40 mg qd, 20 mg twice daily (bid), or placebo for 14 consecutive days. The primary efficacy endpoint was the incidence of VTE in the modified intention-to-treat (mITT) population up to 15 days after surgery. VTE was defined as a composite of deep vein thrombosis (determined by venography) and symptomatic pulmonary embolism (confirmed by appropriate objective methods). Patients were also followed up at 90 days for VTE events. The primary safety outcome was the incidence of any bleeding during treatment and the follow-up period. In the mITT populations, the incidence of VTE was 41.9% and 60.8% in the placebo groups after hip or knee arthroplasty, respectively, 25.9% and 44.9% in the enoxaparin 20 mg qd groups, 33.8% and 35.1% in the enoxaparin 40 mg qd groups, and 20.0% and 29.8% in the enoxaparin 20 mg bid groups. Only enoxaparin 20 mg bid significantly lowered the risk of VTE relative to placebo (by 52.2% and 51.0% after hip and knee arthroplasty, respectively). At the 90-day follow-up, no further cases of VTE were reported. In both the hip and knee studies, the four treatment groups did not differ significantly regarding the incidence of patients with any bleeding. Our findings support the use of enoxaparin (20 mg bid daily, commencing 24–36 h postoperatively) in Japanese patients undergoing total hip or knee arthroplasty." @default.
• W2058202320 created "2016-06-24" @default.
• W2058202320 creator A5067693153 @default.
• W2058202320 creator A5076474598 @default.
• W2058202320 creator A5083615429 @default.
• W2058202320 creator A5090352473 @default.
• W2058202320 date "2008-09-01" @default.
• W2058202320 modified "2023-10-18" @default.
• W2058202320 title "Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin" @default.
• W2058202320 cites W105094744 @default.
• W2058202320 cites W1969404715 @default.
• W2058202320 cites W2011655097 @default.
• W2058202320 cites W2022932023 @default.
• W2058202320 cites W2024857678 @default.
• W2058202320 cites W2032253855 @default.
• W2058202320 cites W2050802944 @default.
• W2058202320 cites W2054169479 @default.
• W2058202320 cites W2064755602 @default.
• W2058202320 cites W2166945512 @default.
• W2058202320 cites W2167186199 @default.
• W2058202320 cites W2168416933 @default.
• W2058202320 cites W2170524066 @default.
• W2058202320 cites W2341200743 @default.
• W2058202320 cites W4248750125 @default.
• W2058202320 cites W4253259085 @default.
• W2058202320 doi "https://doi.org/10.1007/s00776-008-1264-0" @default.
• W2058202320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18843459" @default.
• W2058202320 hasPublicationYear "2008" @default.
• W2058202320 type Work @default.
• W2058202320 sameAs 2058202320 @default.
• W2058202320 citedByCount "75" @default.
• W2058202320 countsByYear W20582023202012 @default.
• W2058202320 countsByYear W20582023202013 @default.
• W2058202320 countsByYear W20582023202014 @default.
• W2058202320 countsByYear W20582023202015 @default.
• W2058202320 countsByYear W20582023202016 @default.
• W2058202320 countsByYear W20582023202017 @default.
• W2058202320 countsByYear W20582023202018 @default.
• W2058202320 countsByYear W20582023202019 @default.
• W2058202320 countsByYear W20582023202020 @default.
• W2058202320 countsByYear W20582023202021 @default.
• W2058202320 countsByYear W20582023202022 @default.
• W2058202320 countsByYear W20582023202023 @default.
• W2058202320 crossrefType "journal-article" @default.
• W2058202320 hasAuthorship W2058202320A5067693153 @default.
• W2058202320 hasAuthorship W2058202320A5076474598 @default.
• W2058202320 hasAuthorship W2058202320A5083615429 @default.
• W2058202320 hasAuthorship W2058202320A5090352473 @default.
• W2058202320 hasConcept C120665830 @default.
• W2058202320 hasConcept C121332964 @default.
• W2058202320 hasConcept C141071460 @default.
• W2058202320 hasConcept C142724271 @default.
• W2058202320 hasConcept C168563851 @default.
• W2058202320 hasConcept C203092338 @default.
• W2058202320 hasConcept C204787440 @default.
• W2058202320 hasConcept C27081682 @default.
• W2058202320 hasConcept C2776265017 @default.
• W2058202320 hasConcept C2776884760 @default.
• W2058202320 hasConcept C2778269268 @default.
• W2058202320 hasConcept C2778336525 @default.
• W2058202320 hasConcept C2778825682 @default.
• W2058202320 hasConcept C2778959117 @default.
• W2058202320 hasConcept C2780011451 @default.
• W2058202320 hasConcept C2780868729 @default.
• W2058202320 hasConcept C42219234 @default.
• W2058202320 hasConcept C61511704 @default.
• W2058202320 hasConcept C68312169 @default.
• W2058202320 hasConcept C71924100 @default.
• W2058202320 hasConceptScore W2058202320C120665830 @default.
• W2058202320 hasConceptScore W2058202320C121332964 @default.
• W2058202320 hasConceptScore W2058202320C141071460 @default.
• W2058202320 hasConceptScore W2058202320C142724271 @default.
• W2058202320 hasConceptScore W2058202320C168563851 @default.
• W2058202320 hasConceptScore W2058202320C203092338 @default.
• W2058202320 hasConceptScore W2058202320C204787440 @default.
• W2058202320 hasConceptScore W2058202320C27081682 @default.
• W2058202320 hasConceptScore W2058202320C2776265017 @default.
• W2058202320 hasConceptScore W2058202320C2776884760 @default.
• W2058202320 hasConceptScore W2058202320C2778269268 @default.
• W2058202320 hasConceptScore W2058202320C2778336525 @default.
• W2058202320 hasConceptScore W2058202320C2778825682 @default.
• W2058202320 hasConceptScore W2058202320C2778959117 @default.
• W2058202320 hasConceptScore W2058202320C2780011451 @default.
• W2058202320 hasConceptScore W2058202320C2780868729 @default.
• W2058202320 hasConceptScore W2058202320C42219234 @default.
• W2058202320 hasConceptScore W2058202320C61511704 @default.
• W2058202320 hasConceptScore W2058202320C68312169 @default.
• W2058202320 hasConceptScore W2058202320C71924100 @default.
• W2058202320 hasIssue "5" @default.
• W2058202320 hasLocation W20582023201 @default.
• W2058202320 hasLocation W20582023202 @default.
• W2058202320 hasOpenAccess W2058202320 @default.
• W2058202320 hasPrimaryLocation W20582023201 @default.
• W2058202320 hasRelatedWork W1429872456 @default.
• W2058202320 hasRelatedWork W1990050067 @default.
• W2058202320 hasRelatedWork W2000380123 @default.
• W2058202320 hasRelatedWork W220073818 @default.
• W2058202320 hasRelatedWork W2319766781 @default.

• next